Cytokinetics (CYTK) Director Robert E. Landry Sells 1,000 Shares

What Happened
Robert E. Landry, a director of Cytokinetics (CYTK), sold 1,000 shares in an open-market transaction on September 15, 2026. The shares were disposed at $72.13 per share for a total proceeds of $72,130. This was a sale (routine insider selling is common and does not by itself indicate company performance).

Key Details

• Transaction date: 2026-09-15
• Transaction type/code: Sale — open-market/private sale (S)
• Price per share: $72.13
• Shares sold: 1,000
• Total value: $72,130
• Shares owned after transaction: Not specified in the provided data — see the full Form 4 for post-transaction holdings.
• Footnotes/plan: No 10b5-1 plan, tax-withholding, or other footnotes were provided in the summary data here.
• Filing timeliness: Reported on the same date (timely based on provided filing date).

Context
Open-market sales by directors are common for diversification, tax, or personal-liquidity reasons and are not definitive indicators of company outlook. Purchases generally carry more weight as signals of insider confidence; this record is a routine sale. For full details (post-sale holdings, any footnotes, or plan descriptions), review the complete SEC Form 4 (Accession No. 0001061983-26-000095).